Overview A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients Status: Completed Trial end date: 2021-08-24 Target enrollment: Participant gender: Summary Primary Objectives: To investigate the efficacy of HBM9161 in patients with attack of MG in China Phase: Phase 2 Details Lead Sponsor: Harbour BioMed (Guangzhou) Co. Ltd.